目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T22012 | FLT DYRK Aurora Kinase | ||
7BIO 是靛玉红的衍生物,抑制细胞周期蛋白依赖性激酶5 和糖原合酶激酶-3β。它抑制 Aβ 寡聚体诱导的神经炎症、突触损伤、tau 过度磷酸化、星形胶质细胞和小胶质细胞的活化,并减轻 Aβ 寡聚体诱导的小鼠认知障碍。 | |||
T6039 | EGFR MEK HER Aurora Kinase | ||
TAK-285 是一种新型 HER2 和 EGFR(HER1) 双重抑制剂,IC50 分别为 17 和 23 nM。它可穿过血脑屏障,有抗肿瘤活性,对 HER1/2 的选择性是 HER4 的 10 倍以上。 | |||
T22288 | PLK | ||
(1E)-CFI-400437 dihydrochloride (CFI-400437 dihydrochloride) 是一种选择性和有效的 polo 样激酶 4 (PLK4) 抑制剂,IC50为 0.6 nM。它还抑制 Aurora A、 Aurora B、 KDR 和 FLT-3,IC50分别为 0.37、0.21、0.48 和 0.18 μM,具有抗增殖活性。 | |||
T10412 | Aurora Kinase | ||
Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase). | |||
T16862 | Aurora Kinase | ||
SCH-1473759 is an inhibitor of the aurora (IC50s: 4 and 13 nM for Aurora A and B, respectively). | |||
T12864 | Aurora Kinase | ||
SCH-1473759 hydrochloride 是一种多靶点极光激酶抑制剂,对极光激酶 A 和 B 的 IC50值分别为 4 和13 nM。 | |||
T23426 | Others Aurora Kinase | ||
TC-A 2317 hydrochloride 是 Aurora 激酶 A 的抑制剂,Ki 为 1.2 nM,而 Aurora 激酶 B 的 Ki 为 101 nM。 TC-A 2317 hydrochloride 显示出抗肿瘤活性。 | |||
T6936 | FAK VEGFR FLT Trk receptor Aurora Kinase | ||
PF-03814735 是一种新型、有效和可逆的极光激酶 A 和 B 抑制剂,IC50值分别为0.8和5 nM。 | |||
T21298 | |||
SNS-314, a synthetic small molecule Aurora kinase (AK) inhibitor with potential antineoplastic activity, selectively binds and inhibits AKs A and B, resulting in the inhibition of cell division and proliferation in tumor cells that overexpress AKs. | |||
T63905 | |||
Hesperadin hydrochloride 是一种 Aurora A 和 B 的 ATP 竞争性吲哚酮抑制剂,对 Aurora B 的 IC50 值为 250 nM。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPK-01413 | H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi) | Mouse | HEK293 | ||
Ovalbumin (OVA) has been historically a popular source of such antigens, since OVA can induce both humoral and cellular immune responses based on well-characterised peptide epitopes. The OVA257-264 octapeptide was one of the frst OVA epitopes to be characterised, it has an amino acid sequence SIINFEKL, which is recognised by cytotoxic T lymphocytes. SIINFEKL forms fbrillar assemblies similar to other peptide hydrogels. Te immunoactive properties of this peptide can therefore be related to its self-assembling nature.
|
|||||
TMPK-01412 | HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype.
|
|||||
TMPK-01416 | HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype.
|